Analysis: Merck's statins turn up more muscle side effects than their rivals

Statins have long come with safety worries, but a new analysis shows that Merck & Co.'s ($MRK) products may carry more than their brethren. Pacing side effects data, Advera Health Analytics found that muscle-related side effects--which are commonly linked to the drugs--show up more often in the New Jersey giant's Zocor, Mevacor and Vytorin than in drugs in the rest of the class. More from FiercePharma

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.